Quotient Sciences, a UK-based firm that describes itself as a “drug development and manufacturing accelerator”, has integrated drug substance into its flagship Translational Pharmaceutics platform, uniting it with drug product and clinical testing activities within one organisation under a single project manager. This follows a year after the acquisition of the former Arcinova site at Alnwick. The company said that Translational Pharmaceutics “provides a more streamlined approach from candidate selection through to commercialisation”, enabling users to adjust formulations and dosing in real time.
Quotient has also recently signed a global licensing agreement, permitting TRx Biosciences to use Translational Pharmaceutics in the formulation development and preparation of clinical trials for Oxilio’s OXL001. This follows an agreement to use the platform in developing OXL001 that was signed in October 2021.
Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.